Universe Pharmaceuticals closes acquisition of Best Praise International Limited, issues 4,376,552 shares

• Universe Pharmaceuticals completed its purchase of Best Praise International on June 30, 2026, acquiring 100% of the issued shares.
• Deal consideration was paid in 4,376,552 restricted Class A ordinary shares issued to the recipients.
• Best Praise holds five China patents tied to pharmaceutical compounds and drug-delivery technologies, including age-related and neurodegenerative diseases.
• Post-issuance share count totals 5,008,313 Class A ordinary shares and 16,077 Class B ordinary shares outstanding.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Universe Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-083956), on July 31, 2026, and is solely responsible for the information contained therein.